12. CHANGE IN ACCOUNTING ESTIMATE (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Reduction in Pharma revenue	$ 24,120,434	$ 34,666,653
Increase in net loss after taxes	$ (9,141,562)	$ 7,454,319
Impact on basic net loss per share	$ (0.19)	$ 0.16
Impact on diluted net loss per share	$ (0.19)	$ 0.14
Plasma Industry [Member]
Reduction in Pharma revenue	$ 23,401,068	$ 26,994,929
Change In Accounting Method Accounted For As Change In Estimate [Member]
Increase in net loss after taxes	$ (4,971,630)
Impact on basic net loss per share	$ (0.10)
Impact on diluted net loss per share	$ (0.10)
Change In Accounting Method Accounted For As Change In Estimate [Member] | Plasma Industry [Member]
Reduction in Pharma revenue	$ (6,293,203)
Change In Accounting Method Accounted For As Change In Estimate [Member] | Revenue [Member]
Change in accounting estimate description	The Company changed its estimate of breakage for recognizing settlement income for Pharma programs based on substantially different performance indicators observed, current trends in the industry regarding program management by third parties, and new information available in dollar loads and spending patterns compared to historical experience.